N,N-Dimethylaethylthioacetamid | 33672-78-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-Dimethylaethylthioacetamid
• 英文别名: 2-ethylsulfanyl-N,N-dimethylacetamide
• CAS: 33672-78-5
• 化学式: C₆H₁₃NOS
• 分子量: 147.241
• InChiKey: KHECDVQHIQXMGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-Dimethylaethylthioacetamid 在 乙醚 、 lithium diethoxyaluminum hydride 作用下， 生成 ethylsulfanyl-acetaldehyde
  参考文献：
  名称：

  LITHIUM DIETHOXYALUMINOHYDRIDE AS A SELECTIVE REDUCING AGENT—THE REDUCTION OF DIMETHYLAMIDES TO ALDEHYDES

  摘要：

  DOI：

  10.1021/ja01511a062

文献信息

• Compounds and methods for modulating nonclassical cadherin-mediated functions
  申请人：Adherex Technologies, Inc.

  公开号：EP1970383A1

  公开（公告）日：2008-09-17

  Modulating agents for inhibiting or enhancing nonclassical cadherin mediacted cell adhesion are provided.

  本研究提供了用于抑制或增强非经典凝集素介导的细胞粘附性的调节剂。
• DE2044718
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUNDS AND METHODS FOR MODULATING OCCLUDIN RELATED TISSUE PERMEABILITY
  申请人：Adherex Technologies, Inc.

  公开号：EP1042365B1

  公开（公告）日：2007-07-25
• PEPTIDOMIMETIC MODULATORS OF CELL ADHESION
  申请人：Gour J. Barbara

  公开号：US20080081831A1

  公开（公告）日：2008-04-03

  Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
• Bmp Gene and Fusion Protein
  申请人：Hidaka Chisa

  公开号：US20080260829A1

  公开（公告）日：2008-10-23

  This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.